GoodNewsoftheDay

True, recent, well-sourced good news, every morning.

HealthLarge human trial1 min read

Incentives double quit rates in lung screening trial

A national clinical trial showed financial incentives nearly doubled smoking cessation rates among underserved adults receiving lung cancer screening.

Researchers enrolled more than 3,200 adults across five medical centers to test four different smoking cessation strategies for participants facing barriers to care.

The group included people with low earnings. They also included those in rural communities. Black or Hispanic adults often struggle to access high-quality health services.

After half a year, 8.8% of those getting free drugs and earning up to 600 dollars stopped smoking. Only 4.3% in standard groups did so. The team confirmed abstinence results by checking blood samples or urine tests for nicotine presence.

Christine Neslund-Dudas noted these patients smoked for many years and had likely failed previous attempts to stop. She stated that these findings provide another useful tool for people who face additional barriers to quitting tobacco use.

Mike Simoff explained that lung cancer screening offers an opportunity to find cancer earlier. It also addresses a major risk factor for many diseases.

When someone comes for screening, staff can discuss quitting and provide the support needed. This change can affect their health for years ahead.

“Financial incentives could give people a tangible reward for their progress and help build confidence that they can keep going.”

Amanda Holm

More health news

HealthLarge human trial1 min read

New weight-loss drug halves knee pain in trials

Two major clinical trials show a new weight-loss drug significantly reduces knee pain for patients with osteoarthritis.

· via ScienceDaily: Top Health

HealthLarge human trial1 min read

New pill offers hope for pancreatic cancer patients

A new drug called daraxonrasib has shown promise in reducing tumour size for people with advanced pancreatic cancer during a recent medical trial.

· via The Guardian: Science